ERBB2 and breast carcinoma: In contrast to other subtypes, TNBC is insensitive to the commonly used breast cancer biomarker-targeting therapies, as it is hormone receptor-negative and lacks human epidermal growth factor receptor 2 (HER2) overexpression.